FDA Compounding Advisory Panel Re-formed With Many Pending Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Fourteen committee members could give advice on Good Manufacturing Practices for registered outsourcing facilities as well as help determine list of drugs that cannot be compounded.
You may also be interested in...
FDA’s Advisory Committee Schedule Hints At Re-formulated Compounding Panel
The agency has not set a meeting date for the Pharmacy Compounding Drugs Advisory Committee, defunct since 2002, in its tentative schedule, but has included 13 vacancies on the panel in its list of committees in need of new members.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.